Merck Manual

Please confirm that you are a health care professional


Generalized Hypopituitarism


Ian M. Chapman

, MBBS, PhD, University of Adelaide, Royal Adelaide Hospital

Last full review/revision Aug 2019| Content last modified Aug 2019
Click here for Patient Education
Topic Resources

Generalized hypopituitarism refers to endocrine deficiency syndromes due to partial or complete loss of anterior lobe pituitary function. Various clinical features occur depending on the specific hormones that are deficient. Diagnosis involves imaging tests and measurement of pituitary hormone levels basally and after various provocative stimuli. Treatment depends on cause but generally includes removal of any tumor and administration of replacement hormones.

(Pituitary structure and function and relationships between the hypothalamus and the pituitary gland are discussed in Overview of the Endocrine System.)

Hypopituitarism is divided into

  • Primary: Caused by disorders that affect the pituitary gland

  • Secondary: Caused by disorders of the hypothalamus

The different causes of primary and secondary hypopituitarism are listed in the table Causes of Hypopituitarism.


Causes of Hypopituitarism



Causes primarily affecting the pituitary gland (primary hypopituitarism)

Pituitary tumors



Infarction or ischemic necrosis

Hemorrhagic infarction (pituitary apoplexy)

Shock, especially postpartum (Sheehan syndrome), or in diabetes mellitus or sickle cell disease

Vascular thrombosis or aneurysm, especially of the internal carotid artery

Inflammatory processes

Meningitis (tubercular, other bacterial, fungal, malarial)

Pituitary abscess

Infiltrative disorders

Idiopathic isolated or multiple pituitary hormone deficiencies


Drugs (eg, hypophysitis due to immune checkpoint inhibitors)


Surgical extirpation

Autoimmune dysfunction

Lymphocytic hypophysitis

Causes primarily affecting the hypothalamus (secondary hypopituitarism)

Hypothalamic tumors




Metastatic tumor


Inflammatory processes

Neurohormone deficiencies of the hypothalamus




Surgical transection of the pituitary stalk


Basal skull fracture

Symptoms and Signs

Symptoms and signs relate to the underlying disorder and to the specific pituitary hormones that are deficient or absent. Onset is usually insidious and may not be recognized by the patient; occasionally, onset is sudden or dramatic.

Most commonly, growth hormone (GH) is lost first, then gonadotropins, and finally thyroid-stimulating hormone (TSH) and adrenocorticotropic hormone (ACTH). Vasopressin deficiency (causing central diabetes insipidus) is rare in primary pituitary disorders but is common with lesions of the pituitary stalk and hypothalamus. Function of all target glands decreases when all hormones are deficient (panhypopituitarism).

Lack of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in children leads to delayed puberty. Premenopausal women develop amenorrhea, reduced libido, regression of secondary sexual characteristics, and infertility. Men develop erectile dysfunction, testicular atrophy, reduced libido, regression of secondary sexual characteristics, and decreased spermatogenesis with consequent infertility.

GH deficiency may contribute to decreased energy but is usually asymptomatic and clinically undetectable in adults. Suggestions that GH deficiency accelerates atherosclerosis are unproved. Effects of GH deficiency in children are discussed elsewhere.

TSH deficiency leads to hypothyroidism, with such symptoms as facial puffiness, hoarse voice, bradycardia, and cold intolerance.

ACTH deficiency results in hypoadrenalism with attendant fatigue, hypotension, and intolerance to stress and infection. ACTH deficiency does not result in the hyperpigmentation characteristic of primary adrenal failure. ACTH deficiency does not result in hyponatremia or hyperkalemia as occurs in primary adrenal insufficiency because the renin-angiotensin-aldosterone pathway remains intact.

Hypothalamic lesions, which can result in hypopituitarism, can also disturb the centers that control appetite, causing a syndrome resembling anorexia nervosa, or sometimes hyperphagia with massive obesity.

Sheehan syndrome, which affects postpartum women, is pituitary necrosis due to hypovolemia and shock occurring in the immediate peripartum period. Lactation does not start after childbirth, and the patient may complain of fatigue and loss of pubic and axillary hair.

Pituitary apoplexy is a symptom complex caused by hemorrhagic infarction of either a normal pituitary gland or, more commonly, a pituitary tumor. Acute symptoms include severe headache, stiff neck, fever, visual field defects, and oculomotor palsies. The resulting edema may compress the hypothalamus, resulting in somnolence or coma. Varying degrees of hypopituitarism may develop suddenly, and the patient may present with vascular collapse because of deficient ACTH and cortisol. The cerebrospinal fluid often contains blood, and MRI documents hemorrhage.


  • MRI or CT

  • Pituitary hormone levels: TSH, prolactin, LH, FSH,

  • Target organ hormone levels: Free thyroxine (T4), testosterone (in men) or estradiol (in women), and cortisol levels plus provocative testing of pituitary-adrenal axis

  • Sometimes other provocative testing

Clinical features are often nonspecific, and the diagnosis must be established with certainty before committing the patient to a lifetime of hormone replacement therapy. Pituitary dysfunction must be distinguished from anorexia nervosa, chronic liver disease, myotonia dystrophica, polyglandular autoimmune disease , and disorders of the other endocrine glands (see table Differentiation of Generalized Hypopituitarism from Other Disorders). The clinical picture may be particularly confusing when the function of more than one gland decreases at the same time. Evidence of structural pituitary abnormalities and of hormonal deficiencies should be sought with imaging and laboratory tests.


Differentiation of Generalized Hypopituitarism from Other Selected Disorders


Differentiating Features

Female predominance; cachexia; abnormal ideation regarding food and body image; maintenance of secondary sexual characteristics despite amenorrhea; increased levels of basal growth hormone and cortisol

Evidence of liver disease; laboratory testing

Myotonia dystrophica

Progressive weakness; premature balding; cataracts; facial features of accelerated aging; laboratory testing

Polyglandular autoimmune disease†

Pituitary hormone levels

* May cause hypogonadism and general debility.

† If the affected glands are target glands of the pituitary.

Imaging tests

Patients should undergo high-resolution CT or MRI, with contrast agent as required (to rule out structural abnormalities, such as pituitary adenomas). Positron emission tomography (PET) is a research tool used in a few specialized centers and therefore is rarely done. When no modern neuroradiologic facilities are available, a simple cone-down lateral x-ray of the sella turcica can identify pituitary macroadenomas with a diameter > 10 mm. Cerebral angiography is indicated only when other imaging tests suggest perisellar vascular anomalies or aneurysms.

Laboratory testing

Initial evaluation should include testing for TSH and ACTH deficiencies, because both conditions are potentially life threatening. Testing for deficiencies of other hormones is also discussed elsewhere.

Free T4 and TSH levels should be determined. Levels of both are usually low in generalized hypopituitarism; a pattern of normal TSH level with low free T4 may also occur. In contrast, elevated TSH levels with low free T4 indicate a primary abnormality of the thyroid gland.

Synthetic thyrotropin-releasing hormone (TRH), 200 to 500 mcg IV given over 15 to 30 seconds, may help identify patients with hypothalamic as opposed to pituitary dysfunction, although this test is not often done. Serum TSH levels are generally measured at 0, 20, and 60 minutes after injection. If pituitary function is intact, TSH should rise by > 5 mU/L, peaking by 30 minutes after injection. A delayed rise in serum TSH levels may occur in patients with hypothalamic disease. However, some patients with primary pituitary disease also show a delayed rise.

Serum cortisol levels alone are not reliable indicators of ACTH-adrenal axis function, although a very low morning serum cortisol level (< 3.5 mcg/dL [96.6 nmol/L] between 7:30 and 9:00 AM) almost certainly indicates cortisol deficiency. One of several provocative tests should be done.

The short ACTH stimulation test is a safer and less labor-intensive test for cortisol deficiency than the insulin tolerance test. In the short ACTH stimulation test, synthetic ACTH 250 mcg IV or IM (standard-dose test) or 1 mcg IV (low-dose test) is given, and the blood cortisol level is measured immediately before and 30 and 60 minutes after administration of the synthetic ACTH. Cortisol should rise significantly; a peak of < 20 mcg/dL (552 nmol/L) is abnormal. However, the short ACTH stimulation test is abnormal in secondary cortisol deficiency only when the test done at least 2 to 4 weeks after onset of the deficiency; before this time, the adrenal glands have not atrophied and remain responsive to exogenous ACTH.

The insulin tolerance test is considered the most accurate way of evaluating ACTH (as well as GH and prolactin) reserve, but because of its demands, it is probably best reserved for patients in whom cortisol does not rise significantly during the short ACTH stimulation test (if confirmation is needed) or when a test must be done within 2 to 4 weeks of a possible pituitary injury. Regular insulin at a dosage of 0.1 units/kg body weight IV is given over 15 to 30 seconds, and venous blood samples are obtained to determine GH, cortisol, and glucose levels at baseline (before insulin administration) and 20, 30, 45, 60, and 90 minutes later. If glucose drops to < 40 mg/dL (< 2.22 mmol/L) or symptoms of hypoglycemia develop, cortisol should increase by > 7 mcg/dL (> 193 nmol/L) or to >20 mcg/dL (> 552 nmol/L). CAUTION: This test is hazardous in patients with severe documented panhypopituitarism or diabetes mellitus and in older people and is contraindicated in patients with coronary artery disease or epilepsy. A health care practitioner should be present during the test. Usually, only transient perspiration, tachycardia, and nervousness occur. If the patient complains of palpitations, loses consciousness, or has a seizure, the test should be stopped promptly by giving 50 mL of 50% glucose solution IV.

Neither the short ACTH stimulation test nor the insulin tolerance test alone will differentiate between primary (Addison disease) and secondary (hypopituitary) adrenal insufficiency. Tests to make this distinction and to evaluate the hypothalamic-pituitary-adrenal axis are described under Addison disease.

The corticotropin-releasing hormone (CRH) test is done to distinguish between primary, secondary (pituitary), and tertiary (hypothalamic) causes of adrenal insufficiency. CRH 1 mcg/kg IV is given by rapid injection. Serum ACTH and cortisol levels are measured 15 minutes before, then at baseline, and 15, 30, 60, 90, and 120 minutes after the injection. Adverse effects include temporary flushing, a metallic taste in the mouth, and slight and transient hypotension.

Prolactin levels are routinely measured. These levels are often elevated up to 5 times normal values when a large pituitary tumor is present, even if it does not produce prolactin. The tumor compresses the pituitary stalk, preventing dopamine, which inhibits pituitary prolactin production and release, from reaching the pituitary. Patients with such hyperprolactinemia often have hypogonadotropism and secondary hypogonadism.

Measurement of basal levels of LH and FSH is most helpful in evaluating hypopituitarism in postmenopausal women not taking exogenous estrogens in whom circulating gonadotropin concentrations are normally high (> 30 mIU/mL [> 30 IU/L]). Although gonadotropin levels tend to be low in other patients with panhypopituitarism, overlap exists with the normal range. Levels of both hormones should increase in response to synthetic gonadotropin-releasing hormone (GnRH) at a dose of 100 mcg IV, with LH peaking about 30 minutes and FSH peaking 40 minutes after GnRH administration. However, normal, diminished, or absent responses to GnRH may occur in hypothalamic-pituitary dysfunction. Normal increases in LH and FSH in response to GnRH vary. Administration of exogenous GnRH is not helpful in distinguishing primary hypothalamic disorders from primary pituitary disorders.

Screening for GH deficiency in adults is not recommended unless GH treatment is contemplated (eg, for unexplained reduced energy and quality of life in patients with hypopituitarism in which other hormones have been fully replaced). GH deficiency is suspected if 2 other pituitary hormones are deficient. Because GH levels vary by time of day and other factors and are difficult to interpret, levels of insulin-like growth factor 1 (IGF-1), which reflect GH, are used; low levels suggest GH deficiency, but normal levels do not rule it out. A provocative test of GH release may be necessary.

Although the usefulness of provocative testing of pituitary function using releasing hormones remains to be established, if such testing is elected, it is most efficient to evaluate multiple hormones simultaneously. Growth hormone–releasing hormone (1 mcg/kg), CRH (1 mcg/kg), TRH (200 mcg), and GnRH (100 mcg) are given together IV over 15 to 30 seconds. Glucose, cortisol, GH, TSH, prolactin, LH, FSH, and ACTH are measured at frequent intervals for the ensuing 180 minutes. The normal responses are the same as those delineated earlier for individual testing.


  • Hormone replacement

  • Treatment of cause (eg, tumor)

Treatment is replacement of the hormones of the hypofunctioning target glands, as discussed in the pertinent chapters in this section and elsewhere in THE MANUAL.

Adults 50 years who are deficient in GH are now sometimes treated with GH doses of 0.002 to 0.012 mg/kg subcutaneously once a day. Benefits of treatment include improved energy and quality of life, increased body muscle mass, and decreased body fat mass. Suggestions that GH replacement can prevent an acceleration of atherosclerosis induced by GH deficiency are unproved.

In pituitary apoplexy, immediate surgery is warranted if visual field disturbances or oculomotor palsies develop suddenly or if somnolence progresses to coma because of hypothalamic compression. Although management with high-dose corticosteroids and general support may suffice in a few cases, transsphenoidal decompression of the tumor should generally be undertaken promptly.

In patients who have had surgery or radiation therapy to treat a pituitary tumor, treatment may be followed by the loss of other pituitary hormone functions. Irradiated patients may lose endocrine function slowly over years. Therefore, posttreatment hormonal status should be evaluated frequently, preferably at 3 and 6 months and yearly thereafter for at least 10 years and preferably up to 15 years after radiation therapy. Such evaluation should include at least assessment of thyroid and adrenal function. Patients may also develop visual difficulties related to fibrosis of the optic chiasm. Sellar imaging and visual field assessment should be done at least every 2 years initially for about 10 years, particularly if residual tumor tissue is present.

Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest


iOS Android
iOS Android
iOS Android